Mutation analyses of 268 candidate genes in human tumor cell lines.

We have performed a homozygous deletion screen on 268 candidate genes in 90 human tumor cell lines derived from multiple types of cancers. Most of the candidate genes investigated have been proposed to be involved in cellular processes that are germane to cancer progression, such as cell cycle control, genome maintenance, chromatin remodeling, cell adhesion, and apoptosis. We have detected novel homozygous deletions affecting four independent loci: Brahma-related gene (SMARCA4) on chromosome 19p in the TSU-Pr1 prostate and A427 lung carcinoma lines, Map Kinase Kinase 3 (MAP2K3) on 17q in the NCI-H774 lung tumor cell line, TMPRSS2 on 21q in the Bx PC-3 pancreatic carcinoma line, and Cadherin 6 (CDH6) on 5p in the SK-LU-1 lung carcinoma line. Subsequent analyses of the coding sequences of these four genes using cDNAs from a panel of tumor cell lines revealed multiple sequence variants. The results of this mutation study serve to demonstrate the feasibility of performing high-throughput screens of candidate genes in tumor cell lines to identify genes that may be targeted for mutation during the development of cancer.

[1]  F Randazzo,et al.  A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. , 2000, Molecular cell.

[2]  D. Teng,et al.  BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. , 2000, Cancer research.

[3]  Alexander Kinev,et al.  BRCA1 Is Associated with a Human SWI/SNF-Related Complex Linking Chromatin Remodeling to Breast Cancer , 2000, Cell.

[4]  J. T. Kadonaga,et al.  The “Dark Side” of Chromatin Remodeling Repressive Effects on Transcription , 1999, Cell.

[5]  W. Stadler,et al.  Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. , 1999, Cancer research.

[6]  M. Yaniv,et al.  The mammalian SWI/SNF complex and the control of cell growth. , 1999, Seminars in cell & developmental biology.

[7]  E. Lees,et al.  Cyclin E Associates with BAF155 and BRG1, Components of the Mammalian SWI-SNF Complex, and Alters the Ability of BRG1 To Induce Growth Arrest , 1999, Molecular and Cellular Biology.

[8]  N Tatsumi,et al.  Cytokine-specific activation of distinct mitogen-activated protein kinase subtype cascades in human neutrophils stimulated by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-alpha. , 1999, Blood.

[9]  M. Redston,et al.  Distinct regions of frequent loss of heterozygosity of chromosome 5p and 5q in human esophageal cancer , 1998, International journal of cancer.

[10]  C. Marshall,et al.  Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2 , 1998, Current Biology.

[11]  Olivier Delattre,et al.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer , 1998, Nature.

[12]  A. Sakurada,et al.  The H-cadherin (CDH13) gene is inactivated in human lung cancer , 1998, Human Genetics.

[13]  R. Hruban,et al.  Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. , 1998, Cancer research.

[14]  J. Nahmias,et al.  Localization of human cadherin genes to chromosome regions exhibiting cancer-related loss of heterozygosity. , 1998, Genomics.

[15]  S. Nishizuka,et al.  Loss of heterozygosity during the development and progression of differentiated adenocarcinoma of the stomach , 1998, The Journal of pathology.

[16]  Anthony E. Reeve,et al.  E-cadherin germline mutations in familial gastric cancer , 1998, Nature.

[17]  Heinz Höfler,et al.  Mutations of the human E‐cadherin (CDH1) gene , 1998, Human mutation.

[18]  M. Skolnick,et al.  Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. , 1997, Cancer research.

[19]  M. Peitsch,et al.  Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. , 1997, Genomics.

[20]  Jan Mollenhauer,et al.  DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3–26.1 is deleted in malignant brain tumours , 1997, Nature Genetics.

[21]  Yusuke Nakamura,et al.  Infrequent Mutation of the H‐Cadherin Gene on Chromosome 16q24 in Human Breast Cancers , 1997, Japanese journal of cancer research : Gann.

[22]  S. Nishizuka,et al.  Commonly deleted regions on the long arm of chromosome 21 in differentiated adenocarcinoma of the stomach , 1997, Genes, chromosomes & cancer.

[23]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[24]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[25]  G. Lanfranchi,et al.  Chromosomal localization of four MAPK signaling cascade genes: MEK1, MEK3, MEK4 and MEKK5. , 1997, Cytogenetics and cell genetics.

[26]  J. Califano,et al.  An allelotype of papillary thyroid cancer , 1996, International journal of cancer.

[27]  T. Liloglou,et al.  Fractional allele loss data indicate distinct genetic populations in the development of non-small-cell lung cancer. , 1996, British Journal of Cancer.

[28]  Sheila Seal,et al.  BRCA2 mutations in primary breast and ovarian cancers , 1996, Nature Genetics.

[29]  M. Skolnick,et al.  Low incidence of BRCA2 mutations in breast carcinoma and other cancers , 1996, Nature Genetics.

[30]  Guha,et al.  Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins , 1996, Molecular and cellular biology.

[31]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[32]  E. Hovig,et al.  CDKN2A (p16INK4A) somatic and germline mutations , 1996, Human mutation.

[33]  D. Louis,et al.  CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.

[34]  M. Bittner,et al.  Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Hirohashi,et al.  Isolation and sequence analysis of human cadherin-6 complementary DNA for the full coding sequence and its expression in human carcinoma cells. , 1995, Cancer research.

[36]  J. Field,et al.  Frequent loss of heterozygosity on chromosome 17 at 17q11.2-q12 in Barrett's adenocarcinoma. , 1995, British Journal of Cancer.

[37]  C. Peterson,et al.  The SWI-SNF complex: a chromatin remodeling machine? , 1995, Trends in biochemical sciences.

[38]  Jiahuai Han,et al.  Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms , 1995, Science.

[39]  Sushovan Guha,et al.  The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest , 1994, Cell.

[40]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[41]  Paul A. Khavari,et al.  BRG1 contains a conserved domain of the SWI2/SNF2 family necessary for normal mitotic growth and transcription , 1993, Nature.

[42]  M. Wigler,et al.  Cloning the differences between two complex genomes , 1993, Science.

[43]  S H Moolgavkar,et al.  Mutation and cancer: a model for human carcinogenesis. , 1981, Journal of the National Cancer Institute.